BBNX•benzinga•
Goldman Sachs Initiates Coverage On Beta Bionics with Neutral Rating, Announces Price Target of $16
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga